Naphazoline + pheniramine


Full Generic Medicine Info
Dosage/Direction for Use

Ophthalmic
Inflammatory condition, ocular, Allergic condition, ocular
Adult: Available preparations: Naphazoline HCl 0.25 mg and pheniramine 3 mg per mL of eye drop solution Naphazoline HCl 0.1 mg and pheniramine 2.2 mg per mL of eye drop solution Instil 1-2 drops in the affected eye(s) up to 4 times daily.
Contraindications
Narrow-angle glaucoma.
Special Precautions
Patient with CV disease, hypertension, diabetes mellitus, hyperthyroidism, benign prostatic hyperplasia, local infection or injury. Children and elderly. Pregnancy and lactation. Concomitant use with MAOIs. Patient Counselling This drug may cause transient effect on vision, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert after 15 minutes.
Adverse Reactions
Significant: Eye irritation, light sensitivity (temporary), tingling sensation, rebound ocular vasodilation or congestion (prolonged or excessive use). Eye disorders: Ocular discomfort, pupil dilatation, increased ocular pressure, mydriasis, keratitis, eye pain, ocular hyperaemia, mydriasis, blurred vision (temporary).
Overdosage
Symptoms (particularly in children): Depression of the CNS with marked reduction in body temperature and bradycardia, excessive sweating, drowsiness, and coma; hypertension followed by hypotension. Management: Symptomatic and supportive treatment.
Drug Interactions
Increased risk of severe hypertensive crisis with MAOIs. Enhanced therapeutic effect with TCAs.
Action
Naphazoline is an α-adrenergic receptor agonist which causes vasoconstriction by stimulating arterioles of the conjunctiva thus reducing swelling, redness and discomfort. Pheniramine is an alkylamine derivative which binds to histamine H1 receptors on conjunctival epithelial cells, thereby reducing ocular itching.
Onset: Conjunctival vasoconstriction: Within 10 minutes.
Duration: Up to 6 hours.
Absorption: Pheniramine: Time to peak plasma concentration: 1-2.5 hours.
Metabolism: Pheniramine: Metabolised to N-desmethylpheniramine, and N-didesmethylpheniramine metabolites.
Excretion: Pheniramine: Via urine (70-83% as unchanged drug and metabolites). Elimination half-life: 16-19 hours.
Storage
Ophthalmic: Store between 15-25°C. Protect from light.
CIMS Class
Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
ATC Classification
S01GA01 - naphazoline ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
R01AB02 - naphazoline ; Belongs to the class of topical sympathomimetic combination preparations, excluding corticosteroids. Used as nasal decongestants.
R01AA08 - naphazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
D04AA16 - pheniramine ; Belongs to the class of topical antihistamines used in the treatment of pruritus.
R06AB05 - pheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on naphazoline + pheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in